Lisa Carey
MD SCM
Medical Director
👥Biography 个人简介
Lisa Carey at UNC has contributed to breast cancer molecular biology and treatment, including contributions to the molecular classification of breast cancer subtypes and to the HER2CLIMB trial establishing tucatinib (HER2 inhibitor) plus trastuzumab-capecitabine — notably showing activity in HER2-positive breast cancer brain metastases, a historically difficult-to-treat complication. Her work addresses important aspects of advanced breast cancer care.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Lisa Carey 的研究动态
Follow Lisa Carey's research updates
留下邮箱，当我们发布与 Lisa Carey（University of North Carolina Lineberger）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment